AnaptysBio, Inc. (NASDAQ:ANAB) to Post Q2 2024 Earnings of ($1.85) Per Share, HC Wainwright Forecasts

AnaptysBio, Inc. (NASDAQ:ANAB) – Stock analysts at HC Wainwright issued their Q2 2024 earnings per share (EPS) estimates for AnaptysBio in a report issued on Monday, July 22nd. HC Wainwright analyst E. Bodnar anticipates that the biotechnology company will post earnings of ($1.85) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.26) per share. HC Wainwright also issued estimates for AnaptysBio’s Q3 2024 earnings at ($1.98) EPS, Q4 2024 earnings at ($2.13) EPS, FY2024 earnings at ($7.60) EPS, FY2025 earnings at ($10.47) EPS, FY2026 earnings at ($5.66) EPS, FY2027 earnings at ($3.85) EPS and FY2028 earnings at ($3.00) EPS.

Several other brokerages have also issued reports on ANAB. JPMorgan Chase & Co. upgraded AnaptysBio from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $29.00 to $69.00 in a research note on Friday, July 19th. Wells Fargo & Company initiated coverage on AnaptysBio in a research note on Thursday, April 11th. They set an “overweight” rating and a $56.00 price target on the stock. Leerink Partnrs restated an “outperform” rating on shares of AnaptysBio in a research note on Tuesday, April 16th. SVB Leerink began coverage on AnaptysBio in a research note on Tuesday, April 16th. They issued an “outperform” rating and a $47.00 price objective on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $34.00 price objective on shares of AnaptysBio in a research note on Friday, May 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, AnaptysBio presently has an average rating of “Moderate Buy” and a consensus target price of $51.89.

AnaptysBio Stock Performance

NASDAQ ANAB opened at $37.23 on Wednesday. AnaptysBio has a twelve month low of $13.36 and a twelve month high of $38.82. The stock has a market capitalization of $1.02 billion, a PE ratio of -6.06 and a beta of -0.25. The stock has a 50-day simple moving average of $26.44 and a 200 day simple moving average of $24.45.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.64) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.10). AnaptysBio had a negative return on equity of 161.40% and a negative net margin of 711.17%. The business had revenue of $7.18 million for the quarter, compared to analyst estimates of $4.55 million.

Insiders Place Their Bets

In other news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction on Thursday, July 18th. The stock was sold at an average price of $35.00, for a total value of $52,500.00. Following the transaction, the insider now owns 11,618 shares of the company’s stock, valued at approximately $406,630. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Hollings Renton sold 1,950 shares of the firm’s stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $23.16, for a total transaction of $45,162.00. Following the sale, the director now owns 1,950 shares of the company’s stock, valued at approximately $45,162. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Paul F. Lizzul sold 1,500 shares of the firm’s stock in a transaction on Thursday, July 18th. The stock was sold at an average price of $35.00, for a total value of $52,500.00. Following the sale, the insider now directly owns 11,618 shares in the company, valued at approximately $406,630. The disclosure for this sale can be found here. In the last quarter, insiders have sold 16,900 shares of company stock valued at $484,824. 33.70% of the stock is currently owned by corporate insiders.

Institutional Trading of AnaptysBio

Hedge funds and other institutional investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC acquired a new stake in shares of AnaptysBio in the 1st quarter valued at about $38,000. China Universal Asset Management Co. Ltd. grew its holdings in AnaptysBio by 350.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 2,390 shares during the period. Quest Partners LLC bought a new position in AnaptysBio during the fourth quarter worth about $119,000. SG Americas Securities LLC bought a new position in AnaptysBio during the fourth quarter worth about $126,000. Finally, Virtu Financial LLC bought a new position in AnaptysBio during the first quarter worth about $222,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.